We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Guardant360 assay will be the preferred circulating tumor DNA (ctDNA) test for liquid biopsy specimens collected in various Pfizer clinical trials after this non-exclusive agreement.